Having trouble reading this email View it in your browser.

Vicor Technologies, Inc.

 

Trade Alert VCRT – Vicor was up as much as 36% on Wednesday, Closing up 17.6%

Volume over 570,000 Shares

 

This follows news yesterday:

Vicor Technologies Announces Agreement With ZOLL Medical Corporation

Leading Global Resuscitation Company to License and Develop Vicor`s PD2i(R) Technology for Use in Its Products

BOCA RATON, Fla., Aug 3, 2011 (GlobeNewswire via COMTEX) — David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB:VCRT), today announced that Vicor and ZOLL Medical Corporation (Nasdaq:ZOLL) have entered into a licensing and development agreement. ZOLL Medical Corporation is the leading global manufacturer of resuscitation and critical care devices and related software solutions, including professional defibrillators and automated external defibrillators (AEDs), the LifeVest(R) Wearable Defibrillator, the AutoPulse(R) Non-invasive Cardiac Support Pump, and Intravascular Temperature Management (IVTM(TM)) equipment. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer(TM), an innovative, non-invasive diagnostic employing Vicor`s patented, proprietary PD2i(R) nonlinear algorithm. Clinical use of the PD2i Analyzer(TM) is supported by an expanding body of literature documenting the PD2i(R) nonlinear algorithm as a valid metric for risk stratifying specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), trauma victims for imminent death absent immediate lifesaving intervention, and ICU patients for mortality risk stratification.

The agreement allows ZOLL to incorporate Vicor`s patented, proprietary PD2i(R) nonlinear algorithm into ZOLL products to enable the ability to predict the risk of future serious events, such as sudden or imminent death in specific patient populations. ZOLL will add Vicor`s PD2i(R) technology in existing and future products to permit real time analysis of patient physiological information and risk prediction to enable earlier intervention in patients and prevent serious events.

“Given the PD2i(R)`s ability to detect a patient`s risk of tachyarrhythmia in time for a warning to be issued to the patient and/or caregiver, we are pleased to be able to utilize this technology in our resuscitation devices, many of which are not only therapeutic but also used to monitor patients prior to an acute event. This technology furthers our ability to not only improve outcomes from sudden cardiac arrest and save people`s lives, but also to predict and prevent such events from occurring,” stated Jonathan A. Rennert, President of ZOLL Medical Corporation.

“We are pleased that our PD2i(R) technology has attracted the attention of ZOLL Medical Corporation, a worldwide leader in the field of resuscitation. ZOLL has been advancing resuscitation care and improving clinical efficiencies since its inception in l980. During this time, ZOLL has introduced numerous technology breakthroughs, such as real time CPR feedback devices, algorithms to identify CPR performance quality, load-distributing band technology for CPR, and, with its ground-breaking Life Vest, a wearable external defibrillator. Much of their technology is driving new standards of care,” stated Mr. Fater.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

About Vicor Technologies, Inc.

Vicor Technologies` PD2i Analyzer(TM) employs its patented, proprietary point correlation dimension algorithm (PD2i(R)), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer(TM) to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

The Vicor Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/pkgid084

Disclaimer

The appearance of name-brand institutions, such as NASDAQ and Forbes, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i(R) values; our ability to generate revenues from the sale of the PD2i Analyzer(TM); our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer(TM); our ability to develop additional applications for the PD2i Analyzer(TM); the ability of additional sales representatives to create revenue; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor`s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Copyright(C) 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.

 

 

# # # CORPORATE CONTACT David H. Fater Vicor Technologies, Inc. 561.995.7313 dfater@vicortech.com INVESTOR CONTACT Richard Moyer Cameron Associates 212.554.5466 richard@cameronassoc.com MEDIA CONTACT Robin Schoen Robin Schoen Public Relations 215.504.2122 rschoen@robinschoenpr.com

 

 

 

 

 

 

 

PRIOR ALERTS:

 

VCRT Continues its Climb – Now Up 105% Since our Shareholder Vision Video Last Monday    

Big Week Last Week for VCRT as it Moves Upward 88% from Monday Low to Friday Close – now up 105% and rising!

Monday saw a low of $0.085.

Today – so far – at: $0.26

 

See the video here:   Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

To view the video interview, please visit: http://www.shareholdervision.com

June 21, 2011 – Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™ , an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicor’s PD2i Analyzer™ to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer™ as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer™ to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing. Sixty published manuscripts of studies involving the use of Vicor’s PD2i® nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit: http://www.shareholdervision.com      

 

  StockGuru`s Profile for Vicor Technologies, Inc. This is the condensed version – Full StockGuru Profile Found Here:

http://www.stockguru.com/about/vcrt/

Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i ® Algorithm and software.

With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.

The Company has all of the regulatory approvals in place already with regards to PD2i ® to generate substantial revenues.

FDA Approval of PD2i Analyzer™ for BOTH Heart Rate Variability and Cardiovascular Disease Testing

Vicor’s PD2i Analyzer™ has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics. And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer™

The potential market for the PD2i Analyzer™ with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer™ for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer™ as a valuable new diagnostic.

The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i ® metric includes the classical Ewing maneuvers with the PD2i ® metric in patients undergoing cardiovascular disease testing.

This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i ® technology by Vicor in 2003.

These populations are significant:

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents

PD2i ® Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care

Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.

Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists. Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications.

Current procedural terminology (CPT) codes enable physicians using the PD2i ® Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

The PD2i ® Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

The PD2i ® Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i ® Algorithm New and Accurate Vital Sign

The Company believes that the PD2i ® Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i ® Algorithm:

First – the PD2i ® Analyzer Second - the PD2i Cardiac Analyzer ™ The PD2i VS ™ Vital Sign Monitor for trauma, triage, and other hospital uses in still  under development.

 

FDA Clearance

In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i ® nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Physician use of the PD2i ® Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i ® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

  This is the condensed version – Full StockGuru Profile Found Here:

http://www.stockguru.com/about/vcrt/     Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com

 

.

Vicor Technologies North Bay Resources VIASPACE, Inc. Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNova About StockGuru: The original service that has become StockGuru started in the late `90`s. At first if was our publisher sharing picks with his friends. Then it grew. Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE . .     Contact StockGuru: P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com

This message was intended for “ You have received this message because you are subscribed to `Stock Guru` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031. <a href="http://www.sgurunews.com/emailmarketer/

IVTM · PRIOR · VCRT · ZOLL

Having trouble reading this email View it in your browser.

Sierra Resource Group Inc. (OTCBB: SIRG)

StockGuru Welcomes Sierra Resource Group (OTCBB: SIRG)

Do not forget to take a close look at SIRG. We will be with Sierra for months to come, but I wanted to make sure you get a chance to see it before the open this morning. Recently we have had a string of successes, and a few of those are highlighted below. Additionally – we have had significant moves in a few others we should mention as well. These include EVCA, AAST, and VUZI. Thanks to the members who pointed those out. I will be sending you more information on Sierra Resource Group this morning, so put this ticker on your radar: SIRG.

SIRG – The Promised Technical and Fundamental Look

Dear Members,

With a company with a chart like that, generally one of three things is going to happen:

1. It is going to move sharply UP soon.

2. It is going to move sharply DOWN soon.

I have an opinion here. First, let`s look at some recent charts for some of our clients. ALL OF THESE CLIENTS ARE WITHIN THE LAST 90 DAYS – Really most are VERY recent:

The above is BRAV, and it actually QUADRUPLED in a week. Price has basically held since. This reverses months and months of a decline.

VCRT above also TRIPLED in recent days. Our Shareholder Vision really brought out the strengths of the Company, and shareholders responded. That was in June.

LYFE has seen extraordinary volume and price increases. This move within the last two weeks.

WRAP is an incredible story of upward movement and momentum. A SOCIAL MEDIA play with a very unique product, and investors are responding.

http://stockguru.com/about/sirg/

Recent releases show me the Company is serious about moving forward. When you look at the mining claims the Company has, you cannot ignore the SIRG. I see an upside here. More on this in the morning.

Any questions Feel free to email me… john@stockguru.com

Thank you,

John Pentony Publisher, StockGuru.com

Profile for Sierra Resource Group Inc. (OTCBB: SIRG) This is the condensed version – Full StockGuru Profile Found Here:

http://stockguru.com/about/sirg/

Sierra Resource Group, Inc. (OTCBB: SIRG) is a U.S. based mining company committed to the exploration, discovery and development of gold, silver, copper and other mineral resources. The company is looking to expand throughout the Americas in the near future. Sierra`s primary asset is 80% ownership of the Chloride Copper Mine. This property is owned outright with no mortgage. The Chloride Copper Mine is located near Kingman, Arizona. Arizona is the nations leading copper producer. In 2007 Arizona was the leading copper-producing state in the US, producing 750 thousand metric tons of copper, worth a record $5.54 billion. Arizona`s copper production was 60% of the total for the United States according to the Arizona Mining Association. The Company`s estimated production costs is $2,240 MT manifest the Chloride Copper Mine has the potential for high margined production and substantial profitability.

Chloride Copper Project – Estimated 27 Million Pounds of Copper Kingman, Arizona Location

The Chloride Copper property consists of thirty-seven unpatented lode mining claims and twelve millsite claims, and is located 24km northwest of Kingman, in the Wallapai District, Mohave County, Arizona. The Chloride Copper Project is a former copper producer comprised of a mineral deposit and some infrastructure located near Kingston, Arizona (the “Copper Mine”). The Acquisition formally closed on June 21, 2010.

Existing Plant on Premises An open pit mine and the existing solvent extraction electrowinning plant processing plant (SX/EW Plant) were operated at the site from 1995 before being idled in 1996 due to low copper prices. Sierra plans to use open pit mining and intends to reopen the existing solvent extraction electrowinning plant processing plant on site at the Copper Chloride Mine. The existing SX/EX plant has a maximum annual capacity of up to 5,400,000 pounds of Copper Cathode. The Plant is environmentally friendly, cost effective and a creates the mechanics for a extremely quick production process according to an article published by the Copper Development Association in August 2001.

Technical Report Indicates 27 Million Pounds of Copper

The Chloride Copper Mine Technical Report, NI43-101, authored and prepared by Scott Wilson Roscoe Postle Associates dated March 10, 2006, estimates the Chloride Copper Mine contains 27 Million pounds of copper. (For Chloride Copper Mine Technical Report Link here: http://sierraresgroup.com/diligence/Emerald%20Isle/ei43-101.pdf )

T his is the condensed version – Full StockGuru Profile Found Here:

http://stockguru.com/about/sirg/

Contact Sierra Resource Group Inc. (OTCBB: SIRG)

Sierra Resource Group, Inc.

Patrick Champney | Chief Executive Officer patrick@sierraresgroup.com 9550 S. Eastern Ave.

Suite 253 Las Vegas, NV , 89123 Website: http://www.sierraresgroup.com Phone: 702-462-7285

 

Sierra Resource Group BRAVADA International WrapMail, Inc. EVCARCO, Inc. Vicor Technologies North Bay Resources VIASPACE, Inc. Vuzix Corporation Mantra Venture Group About StockGuru: The original service that has become StockGuru started in the late `90`s. At first if was our publisher sharing picks with his friends. Then it grew. Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE . .     Contact StockGuru: P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com

This message was intended for “ You have received this message because you are subscribed to `Stock Guru` Safe Harbor Statement under the Private Litigation Reform Act of 1995. Forward-looking statements in this document do not constitute guarantees of future performance. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. You can anticipate that actual results will be different due to the inherent uncertainty of estimates; forecasts and projections may be better or worse than projected. Forward-looking statements may relate, among other things, to expected financial and operating results and the Company’s ability to achieve its goals, plans and objectives. The risks and uncertainties that may affect forward-looking statements include among others: the Company’s limited operating history, the speculative nature of the Company’s planned operations, difficulty in developing new projects, difficulty gaining necessary governmental approvals, the Company’s lack of market research and marketing organization, the Company’s inexperience in operating internationally, and difficulty managing rapid growth. At this time, there can be no assurance that the Company will obtain the financing it needs to execute its plans. For a more detailed discussion of the risks and uncertainties of Sierra Resource Group’s business, please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, and the Company’s Reports on Form 8-K, all filed with the Securities and Exchange Commission, and as subsequently amended. The Company assumes no obligation to update any forward-looking statement contained in this document or with respect to any of the information described herein.

SIRG Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with SIRG. We hold not shares and will not be receiving any shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. The Company has compensated us forty seven hundred dollars and will likely be compensating us a total of twelve thousand dollars additionally before the end of 2011 for coverage. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031. Disclosure for BRAV: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with Bravada (“The Company”). The company has agreed to past and current compensation totaling ninetee thousand five hundred dollars from the company for profile coverage. We currently hold not shares and have taken no additional shares, nor have we purchases any in the market. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share while we are covering this company. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In the past we have been compensated 750,000 free trading shares from a non-controlling third party – not the company. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Our contact information is Pentony Enterprises; 1601 Berwick Drive; McKinney, Texas 75070; Telephone 469-252-3030. WRAP Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with WRAP. We hold not shares and will not be receiving any shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. The Company will compensate us a total of eleven thousand three hundred dollars for coverage. After ninety days, the client may opt to extend coverage at forty four hundred dollars per month. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031. VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031.

<a href="http://www.sgurunews.com/emailmarketer/

AAST · BRAV · EVCA · LYFE · SIRG · VCRT · VUZI

Having trouble reading this email View it in your browser.

Allied American Steel Corp (OTCBB: AAST)

StockGuru Welcomes Allied American Steel Corporation

I wanted to bring one to your attention today that has sold off in recent days.

Let`s start with a technical look at AAST: When you see a sell-off of this kind, you are looking for the same hook that could pull it back up – as with our VCRT last week (continued into this week) with its more than 200% gain over recent lows. That hook comes typically as volume slows on the decline, and volume increases in a day or two of price increases.

That – of course – should it happen as I suggest it could, totally depends on what your position is. 

We are going to look at the fundamentals of the Company shortly. MORE ON THAT PRIOR TO MARKET OPEN.

Profile for Allied American Steel Corp This is the condensed version – Full StockGuru Profile Found Here:

http://stockguru.com/about/aast/

Allied American Steel Corp is an exploration stage company focused on the discovery and production of significant iron ore resources, and the titanium dioxide resources often associated with iron deposits. Based in Pittsburgh, PA, the Company is positioned to continue the strategic expansion of its property portfolio in close proximity to North America’s eastern seaboard, granting easy access to world export markets. Allied American Steel is publicly traded, and can be found on the NASDAQ OTC BB under the ticker symbol AAST.

Allied American Steel has the right to acquire a 60% undivided interest in the Lake Touladi Property. The property represents 48 contiguous mineral claims totaling 6,773 acres (2,741 hectares). The claims are located in close proximity to the eastern seaboard in the Canadian province of Quebec, granting easy access to world export markets. A 43-101 technical report (May, 2010) commissioned by the sellers of the option cited the identification during the 1950’s of 4 major mineralized zones (A to D) on the property.

The combined estimated historical mineral resources* for Zones A and B alone, which were only partially drilled, were cited by the report as 124 million tons (Mt) grading an average 23.3 wt. % iron (Fe) and 6.6 wt. % titanium dioxide (TiO2).1 Two drill holes on the property (A4 and A6) reached a depth of 300 meters, and intersected mineralization having the same type and grade as the historical 124 Mt resource, indicating there is a potential to at least double the previous historical estimate to the 248 Mt estimate cited by the sellers. Based on new exploration work, including an airborne magnetic survey in 2008 that indicates important undiscovered mineralized zones, the 43-101 report concludes the Lake Touladi Fe-Ti deposit represents a high potential asset, and possesses the geological characteristics necessary to become a world-class open pit mine.

The report goes on to state that the property’s historical resource estimates can be substantially increased by drilling the expanded anomalous high reading magnetic zones identified in the airborne survey.1 Allied American is currently planning a 2,500-meter drilling program for 2011, and will be mobilizing a rig to the property in the next few months to verify and expand the historical estimate while bringing it into compliance with CIM definitions.The Company will also be investigating the potential recovery of ilmenite, an iron titanium oxide mineral, from the titanium-rich portions of the mineralized zone (previous concentration tests were performed only for magnetic separation of iron).

Previous Exploration Four major mineralized zones (A to D) where initially discovered on the Lake Touladi Property in the 1950’s by ground based exploration, magnetic surveying and drilling.

Roberval Mining Corporation completed 1,800 meters of drilling, concentrated mainly in the A and B zones. A total of 18 short holes were drilled to depths ranging from 18 to 30 meters at widely separated points in the two zones. When using a cut off depth of only 160 meters, the overall resource in zones A and B (2 of the 4 zones initially discovered) was established by O’brien et al (1975) as 124 million tons (Mt). The average grade established was 23.3 wt. % Fe and 6.6 wt. % TiO2.1 A further 1,480 meters have been drilled in 6 long holes (A1 to A6) across zones A and B, testing them for vertical continuity to over 300 meters; the holes ended in mineralization.1 In particular, holes A4 and A6 intersected mineralization at a depth of 300 meters of the same type and grade as the historical estimate 124 Mt resource, indicating there is a potential to at least double the previous historical estimate to the 248 Mt estimate cited by the sellers.

Current Exploration New exploration work at the Lake Touladi Fe-Ti deposit, including an airborne magnetic survey, suggests important undiscovered mineralized zones that seem to have been largely ignored during the previous exploration work. These zones are associated with strong magnetic low signatures covering a large area (3km x 0.5km) and probably related to ilmenite-rich (iron and titanium oxide mineral) or reversely polarized Ti- magnetic-rich mineralized bodies at shallow depth. SEM Quantitative analyses of the oxide minerals indicate that pure ilmenite with the chemical composition reaching that of the theoretical ilmenite may form more than 65% of the mineralization. As for mineralization processing, iron would be extracted principally from Ti-poor magnetite and titanium; from pure ilmenite; and perhaps titanomagnetite and ilmenohematite.

The interpretation of the new aeromagnetic survey in combination with the examination of previous surveys and drilling campaigns shows that:

the areas defined by strong negative anomalies, which are probably related to the presence of hemoilmenite (titanium) mineralization at depth, were not investigated by previous drilling zones characterized by strong positive anomalies were only partially explored there is another NS-oriented zone located 1km west of the main showing that displays a similar pattern of alternating magnetic highs and lows, deserving further investigation

This is the condensed version – Full StockGuru Profile Found Here:

http://stockguru.com/about/aast/

Contact Allied American Steel Corp

Allied American Steel Corp

E-mail: info@alliedamericansteel.com Web: www.alliedamericansteel.com

INVESTOR RELATIONS Toll Free: 1-800-256-7207 E-mail: ir@alliedamericansteel.com

 

 

Allied American Steel WrapMail, Inc. EVCARCO, Inc. Vicor Technologies North Bay Resources VIASPACE, Inc. Vuzix Corporation Mantra Venture Group About StockGuru: The original service that has become StockGuru started in the late `90`s. At first if was our publisher sharing picks with his friends. Then it grew. Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE . .     Contact StockGuru: P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com

This message was intended for “ You have received this message because you are subscribed to `Stock Guru` AAST Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract a third party to feature AAST. We own no shares and will not be compensated in shares. To avoid all potential conflicts of interest, we never buy or sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. We will be compensated up to five thousand dollars through July 8, 2011. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031.

<a href="http://www.sgurunews.com/emailmarketer/

AAST · PRIOR · VCRT

%3D
Watch List for Wednesday 6-29-2011

I will be releasing my BIG holiday report this Wednesday night.

VCRT – Momentum
http://finance.yahoo.com/qs=VCRT.OB
Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution.

*************************

TBBC – Momentum
http://finance.yahoo.com/qs=TBBC.OB
The Brainy Brands Company, Inc. develops and markets an extensive library of early childhood learning products, including a full range of puzzles, books, games, toys and audio-visual materials for the US.

*************************

GLUU – Volume Alert
http://finance.yahoo.com/qs=GLUU
Glu Mobile Inc. engages in the design, marketing, and sale of mobile games worldwide

*********************************************************

This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: Hototc.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Hototc.com does not provide trading, investment or tax advice, and readers shall not rely on statements by Hototc.com employees which purport to provide such advice. Full disclaimer can be read at http://www.Hototc.com/disclaimer.htm

Release of Liability: Through use of this website viewing or using you agree to hold Hototc.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Hototc.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Hototc.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Hototc.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Hototc is compliant with the Can Spam Act of 2003. Hototc.com does not offer such advice or analysis, and Hototc.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor`s investment may be lost or impaired due to the speculative nature of the companies profiled.

Hototc.com has not been compensated today for any of the companies mentioned in this particular email. Hototc.com owns no shares in these companies.

All direct and third party compensation received will be disclosed within each individual email in accordance with section 17(b) of the 1 9 3 3 Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Hototc.com has not investigated the background of the third party, the hiring company. Anyone viewing our website and advertisement should assume that the hiring party and affiliates of the hiring party own shares of the profiled company of which they plan to liquidate, further understanding that the liquidation of those shares will most likely impact the share price of the profiled company negatively. Hototc.com affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the share price of the security.

The Private Securities Litigation Reform Act of 1995 provides investors a `safe harbor` in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, Hototc.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Hototc.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Hototc.com is not responsible for any claims made by the companies advertised herein, nor is Hototc.com responsible for any other promotional firm, its program or its structure.

GLUU · TBBC · VCRT

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S57&L=3&N88 Having trouble reading this email View it in your browser.

a Vicor Technologies, Inc.

[vcrt-midday-MEDIUM] VCRT Continues its Climb – Now Up 105% Since our Shareholder Vision Video Last Monday Big Week Last Week for VCRT as it Moves Upward 88% from Monday Low to Friday Close – now up 105% and rising! Monday saw a low of $0.085.

Today – so far – at: $0.175 See the video here:

Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L03&F=T June 21, 2011 Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i nonlinear algorithm.

Physician use of the PD2i Analyzer is supported by an expanding body of literature documenting the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicors PD2i Analyzer to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing. Sixty published manuscripts of studies involving the use of Vicors PD2i nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L03&F=T StockGuru`s Profile for Vicor Technologies, Inc.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L69&F=T Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i Algorithm and software.

With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.

The Company has all of the regulatory approvals in place already with regards to PD2i to generate substantial revenues.

FDA Approval of PD2i Analyzer for BOTH Heart Rate Variability and Cardiovascular Disease Testing Vicors PD2i Analyzer has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.

And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer The potential market for the PD2i Analyzer with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer as a valuable new diagnostic.

The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i metric includes the classical Ewing maneuvers with the PD2i metric in patients undergoing cardiovascular disease testing.

This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i technology by Vicor in 2003.

These populations are significant:

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents PD2i Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.

Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.

Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

The PD2i Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

The PD2i Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i Algorithm New and Accurate Vital Sign The Company believes that the PD2i Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i Algorithm:

First – the PD2i Analyzer Second – the PD2i Cardiac Analyzer The PD2i VS Vital Sign Monitor for trauma, triage, and other hospital uses in still under development.

FDA Clearance In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Physician use of the PD2i Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N57&L69&F=T Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com ..

a Vicor Technologies North Bay Resources VIASPACE, Inc.

Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNovaAbout StockGuru:

The original service that has become StockGuru started in the late `90`s.

At first if was our publisher sharing picks with his friends. Then it grew.

Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE.

..

Contact StockGuru:

P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com This message was intended for “ You have received this message because you are subscribed to `Bold Stocks Alerts` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

VCRT